BIOGEN INC said its Alzheimer's drug did not meet the main goal of a mid-stage trial. The setback affects the company's neurology portfolio expansion. Drug failures can shift investor focus to other pipeline candidates.

Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration